Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

M. R. Sydes, M. R. Spears, M. D. Mason, N. W. Clarke, D. P. Deanaley, J. S. de Bono, G. Attard, S. Chowdhury, W. Cross, S. Gillessen, Z. I. Malik, R. Jones, C. C. Parker, A. W. S. Ritchie, J. M. Russell, D. Milliman, D. Matheson, C. Amos, C. Gilson, A. Birtle, S. Brock, L. Capaldi, P. Chakraborti, A. Choudhury, L. Evans, D. Ford, J. Gale, S. Gibbs, D. C. Gilbert, R. Hughes, D. McLaren, J. F. Lester, A. Nikapota, J. O’Sullivan, O. Parikh, C. Peedell, A. Protheroe, S. M. Rudman, R. Shaffer, D. Sheehan, M. Simms, N. Srihan, R. Strebel, S. Sündar, S. Tolan, D. Tsang, M. Varughese, J. Wagstaff, M. K. B. Parmar, N. D. James & The STAMPEDE Investigators

Background: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation of drug efficacy: a multi-arm multi-stage platform randomised controlled protocol recruiting patients with high-risk locally advanced or metastatic PCa starting long-term androgen deprivation therapy (ADT). The protocol provides the only direct, randomised comparative multi-arm multi-stage platform randomised data from the STAMPEDE multi-arm, multi-stage platform randomised controlled protocol recruiting patients with high-risk locally advanced or metastatic PCa starting long-term ADT. The primary outcome for most non-metastatic cases, ADT for ≥2 years and RT to the primary tumour. Stratified randomisation allocated pts 2 : 1 : 2 to AAP versus SOC; AAP overlapped November 2011 to March 2013. SOC was long-term ADT or, for most non-metastatic cases, ADT for ≥2 years and RT to the primary tumour. Stratified randomisation allocated pts 2 : 1 : 2 to SOC + AAP versus SOC + DocP.

Method: Recruitment to SOC + DocP and SOC + AAP overlapped November 2011 to March 2013. SOC was long-term ADT or, for most non-metastatic cases, ADT for ≥2 years and RT to the primary tumour. Stratified randomisation allocated pts 2 : 1 : 2 to SOC + docetaxel 75 mg/m² 3-weekly × 6 + prednisolone 10 mg daily; or SOC + abiraterone acetate 1000 mg + prednisolone 5 mg daily. AAP duration depended on stage and intent to give radical RT. The primary outcome

© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
measure was death from any cause. Analyses used Cox proportional hazards and flexible parametric models, adjusted for stratification factors. This was not a formally powered comparison. A hazard ratio (HR) < 1 favours SOC + AAP, and HR > 1 favours SOC + DocP.

**Results:** A total of 566 consenting patients were contemporaneously randomised: 189 SOC + DocP and 377 SOC + AAP. The patients, balanced by allocated treatment were: 342 (60%) M1; 429 (76%) Gleason 8–10; 449 (79%) WHO performance status 0; median age 66 years and median PSA 56 ng/ml. With median follow-up 4 years, 149 deaths were reported. For overall survival, HR = 1.16 (95% CI 0.82–1.65); failure-free survival HR = 0.51 (95% CI 0.39–0.67); progression-free survival HR = 0.65 (95% CI 0.48–0.88); metastasis-free survival HR = 0.77 (95% CI 0.57–1.03); prostate cancer-specific survival HR = 1.02 (0.70–1.49); and symptomatic skeletal events HR = 0.83 (95% CI 0.55–1.25). In the safety population, the proportion reporting ≥ 1 grade 3, 4 or 5 adverse events ever was 36%, 13% and 1% SOC + DocP, and 40%, 7% and 1% SOC + AAP; prevalence 11% at 1 and 2 years on both arms. Relapse treatment patterns varied by arm.

**Conclusions:** This direct, randomised comparative analysis of two new treatment standards for hormone-naive prostate cancer showed no evidence of a difference in overall or prostate cancer-specific survival, nor in other important outcomes such as symptomatic skeletal events. Worst toxicity grade over entire time on trial was similar but comprised different toxicities in line with the known properties of the drugs.

**Trial registration:** Clinicaltrials.gov: NCT00268476.

**Key words:** prostate cancer, randomised, treatment, abiraterone, docetaxel, head-to-head

---

**Research in context**

**Evidence before this study**

Abiraterone acetate plus prednisone/prednisolone (AAP) and docetaxel with prednisone/prednisolone (DocP) have separately been shown to improve survival when used in addition to the previous international standard-of-care (SOC) for hormone-sensitive prostate cancer of androgen deprivation therapy with further therapy such as AAP or DocP on relapse. This has been confirmed in a number of separate trials and on meta-analysis. The largest body of evidence for both AAP and DocP comes from the systemic therapy for advanced or metastatic prostate cancer: evaluation of drug efficacy (STAMPEDE) platform trial.

**Added value of this study**

Recruitment to DocP and AAP overlapped in STAMPEDE giving the only head-to-head evidence comparing these two new standard treatment approaches. We report data from the 566 patients who were directly randomised between these two treatment approaches while the two research arms were both open to recruitment. The data show strong evidence favouring SOC + AAP on earlier, more biochemically driven outcome measures (OMs). For longer-term, more clinically driven OMs, including bone complications, prostate cancer-specific and overall survival, there is no evidence of a significant difference between AAP and DocP.

**Implications of all the available evidence**

The reported trials and meta-analyses showed a larger effect on survival for AAP over the previous SOC than did DocP over the standard SOC. These data show that the story may be more complicated. No other directly randomised data on survival of these treatments are available. Individual patient data network meta-analysis using all of the published trials are warranted, accounting for differences in patient characteristics, treating clinicians and centres and salvage treatment access. The STAMPEDE team is collaborating with the STOPCAP meta-analysis group to achieve this.

---

**Introduction**

For several decades, the standard-of-care (SOC) for most patients with high-risk locally advanced or metastatic prostate cancer has been long-term androgen deprivation therapy (ADT) alone. The past few years, there have been great changes, first with results from randomised controlled trials (RCTs) showing a survival advantage compared with ADT alone for adding radiotherapy to the prostate in men with non-metastatic disease and no known nodal involvement [1–3]; then with systemic treatments for all men starting long-term hormone therapy: docetaxel plus prednisolone/prednisone (DocP) [4–9] and, most recently, abiraterone acetate plus prednisolone/prednisone (AAP) [10, 11]. As both therapeutic combinations are effective, there are now two distinct standards-of-care with little information to guide clinicians as to which is the more effective; there are no prospective, powered, RCTs that will deliver direct comparative data.

Systemic therapy for advanced or metastatic prostate cancer: evaluation of drug efficacy (STAMPEDE) is a multi-arm, multi-stage platform protocol which assessed both of these treatment approaches, separately, against the previous SOC [12, 13]. The ‘docetaxel comparison’ of STAMPEDE recruited patients allocated to SOC + DocP between October 2005 and March 2013. The ‘abiraterone comparison’, the first comparison to be added to STAMPEDE, recruited patients allocated to SOC or SOC + AAP between November 2011 and January 2014. Each of those comparisons had primary outcome measure (OM) of overall survival (OS) for the patients randomised contemporaneously to the control arm and the relevant research arm. Consequently, between 15 November 2011 and 31 March 2013, patients were directly randomised contemporaneously between these two research arms (and other research arms) and we now present these data.
Methods

Trial design

The STAMPEDE protocol and design have been described in detail elsewhere [7, 10, 12, 14]. Briefly, STAMPEDE comprises a series of multi-arm multi-stage (MAMS) comparisons that have overlapped in recruitment and follow-up time.

Patient selection

Eligible patients were those starting long-term ADT for the first time. This was defined as patients with metastatic disease, nodal involvement or node negative, non-metastatic disease with two or more of three high-risk features: T-category 3 or 4, Gleason sum score 8–10 or PSA > 40 ng/ml. Patients rapidly relapsing after previous local therapy were also permitted if they had PSA > 20 ng/ml or PSA > 4 ng/ml with a PSA doubling time < 6 months or those who developed loco-regional or metastatic spread whilst not on hormone therapy.

As with all STAMPEDE comparisons, the primary OM of the two underpinning comparisons (against control) was OS. Failure-free survival (FFS) was an intermediate primary OM, defined as time from randomisation to the first of: rising PSA (where rising PSA was defined as a confirmed rise to > 4 ng/ml, and > 50% above the lowest value in the first 6 months after randomisation); new disease or progression of: distant metastases, lymph nodes or local disease; or death from prostate cancer. Progression-free survival (PFS) was defined as time from randomisation to the first of: new disease or progression of: distant metastases, lymph nodes or local disease; or death from prostate cancer [15]. Metastatic PFS (MPFS) was defined as time from randomisation to death from any cause, new metastases or progression of distant metastases.

All patients provided written informed consent; all versions of the protocol have been reviewed by the relevant research ethics committees and the regulatory agencies; the original protocol and all subsequent versions involving the introduction of a new research arm and comparison were independently peer-reviewed by Cancer Research UK (CRUK).

Patients have been allocated across a number of research treatments as depicted in Figure 1. Here we focus on those patients randomised between 15 November 2011 and 31 March 2013, while both the ‘docetaxel comparison’ and the ‘abiraterone comparison’ were open to recruitment, and who were allocated to either SOC + DocP or SOC + AAP.

Trial treatment, masking and follow-up

The SOC was long-term hormone therapy with LHRH analogues (with short term antiandrogen if relevant) or orchidectomy. Unless contraindicated, radiotherapy to the prostate was mandated in all patients with N0M0 disease, encouraged in patient with N + M0 disease, and permitted in patients with M1 disease until the activation of the ‘M1/RT comparison’ in January 2013. On the DocP arm, docetaxel (75 mg/m²) was given once every 3 weeks for six cycles, with prednisolone/prednisone (10 mg) daily. On the AAP arm, abiraterone acetate (1000 mg) with prednisolone/prednisone (5 mg) daily was given until PSA, clinical and radiological progression or a change of treatment. AAP duration was capped after 2 years in M0 patients having radical radiotherapy. Modifications for toxicities were described in the protocol and previous papers [7, 10]. Treatment allocation was not masked for practical reasons. Patients were seen 6-weekly at first, dropping to 6-monthly after 2 years. Imaging scans after baseline were at the investigator’s discretion.

Randomisation

Patients were randomised centrally using minimisation with a random element across a number of stratification factors using unequal allocation (previously described) [7, 10]. The allocation ratio was initially 2 : 1 control : research; the ‘abiraterone comparison’ was brought in with an equal allocation (1 : 1) ratio to the control. Therefore the allocation ratio here is 1 : 2 for SOC + DocP : SOC + AAP.

Statistical analysis

The comparison presented here is of SOC + AAP against SOC + DocP because both of these arms have demonstrated better OS than their contemporaneous controls in the population of men starting long-term hormone therapy. The protocol specified that research arms which were better than the control arm could be compared, following a closed test approach. The maturity of the data used for SOC + AAP matches that recently reported [10] in the primary results and is updated to the same data freeze timepoint for SOC + DocP so is longer-term data than previously reported results for this arm [7].

The previously-reported comparisons of SOC + DocP versus SOC and SOC + AAP versus SOC had formal sample size calculations; there is no formal sample size calculation for this comparison: it is an opportunistic comparison between the contemporaneously recruited research arm patients. Although the recruitment overlap is only 17 months, 566 patients were allocated to the 2 research arms of interest and thus contribute substantial information to inform this comparison.

Standard survival analysis methods were used, following the approach for each of these underpinning comparisons; hazard ratios (HR) were estimated from adjusted Cox models, after checking that the proportional hazards assumption held, where an HR < 1 represents evidence in favour of SOC + AAP and HR > 1 represents evidence in favour of SOC + DocP. Nominal confidence intervals are presented at the 95% level. A P-value < 0.1 was considered indicative of treatment-baseline characteristic interaction, recognising the limited power of the heterogeneity tests. Efficacy analyses were done in the intention-to-treatment basis, by allocated treatment. Safety analyses were done only in patients who started their allocated treatment.

Results

Accrual and characteristics

The dataset for this comparison was frozen on 10 February 2017. Between 15 November 2011 and 31 March 2013, 1348 patients joined all open arms STAMPEDE. Of the 566 randomised to the comparison reported here, 189 (14%) were allocated to SOC + DocP, 377 (28%) to SOC + AAP. The flow of patients to this comparison is shown in Figure 2. Table 1 shows the baseline characteristics of patients in this comparison which differ only slightly from the previous papers (summarised in supplementary Table S1, available at Annals of Oncology online). Median follow-up, calculated by reverse censoring on survival, was 48 months.

Overall survival

There were 44/189 (23%) deaths on the SOC + DocP arm and 105/377 (28%) deaths on the SOC + AAP arm. The estimated HR = 1.16 (95% CI 0.82–1.65; P = 0.40) (Figure 3A). Estimates in patients with and without metastases are shown in Table 2, with HR = 1.51 (95% CI 0.58–3.93) in M0 patients and HR = 1.13 (95% CI 0.77–1.66) in M1 patients. There was no evidence of interaction in the treatment effect by baseline metastases (P = 0.69).

Totally, 126/149 deaths were attributed to prostate cancer, comprising 10/22 and 116/127 deaths in patients with M0 and M1 disease at entry, respectively. Competing risks regression shows no evidence of a difference in prostate cancer-specific
**Figure 1.** Activity-by-time diagram: patients included in this comparison. SOC, standard-of-care; Doc, docetaxel; Abi, abiraterone acetate-prednisone/prednisolone. Boxes represent periods of recruitment (x-axis) to each of the trial arms (y-axis). The blue boxes represent recruitment periods contributing to this analysis; the green boxes other recruitment period, past and future, contributing to other aspects of the STAMPEDE. The squares represent the time point of the first key comparative analyses for each comparison in pink and for this comparison in blue.

**Figure 2.** CONSORT diagram. SOC, standard-of-care; DocP, docetaxel-prednisolone/prednisone; AAP, abiraterone acetate-prednisolone/prednisone. Selection of patients for this comparison.
Table 1. Baseline characteristics of patients allocated to SOC + DocP or SOC + AAP by whether contributing to the direct comparison

| Characteristic          | SOC + DocP | SOC + AAP | Overall |
|-------------------------|------------|-----------|---------|
|                         | N          | %         | N       | %         | N       | %         |
| Metastases              |            |           |         |           |         |           |
| M0                      | 74         | 39        | 150     | 40        | 224     | 40        |
| M1                      | 115        | 61        | 227     | 60        | 342     | 60        |
| Nodal stage             |            |           |         |           |         |           |
| N0                      | 82         | 43        | 158     | 42        | 240     | 44        |
| N+                      | 99         | 52        | 202     | 53        | 301     | 56        |
| NX                      | 8          | 4         | 17      | 5         | 25      | n/a       |
| Combination             |            |           |         |           |         |           |
| N0 M0                   | 43         | 23        | 84      | 22        | 127     | 22        |
| N+M0                    | 31         | 16        | 66      | 18        | 97      | 17        |
| N0 M1                   | 39         | 21        | 74      | 20        | 113     | 20        |
| N+ M1                   | 68         | 36        | 136     | 36        | 204     | 36        |
| NX M1                   | 8          | 4         | 17      | 5         | 25      | 4         |
| Tumour category         |            |           |         |           |         |           |
| <T3                     | 24         | 13        | 36      | 10        | 60      | 11        |
| T3                      | 123        | 65        | 249     | 66        | 372     | 69        |
| T4                      | 39         | 20        | 68      | 18        | 107     | 20        |
| Tx                      | 3          | 2         | 24      | 6         | 27      | n/a       |
| Gleason category        |            |           |         |           |         |           |
| ≤7                      | 35         | 19        | 91      | 25        | 126     | 23        |
| 8–10                    | 153        | 81        | 276     | 75        | 429     | 76        |
| Unknown                 | 1          | —         | 10      | —         | 11      | n/a       |
| Previous local therapy  |            |           |         |           |         |           |
| No                      | 183        | 97        | 350     | 93        | 533     | 94        |
| Yes                     | 6          | 3         | 27      | 7         | 33      | 6         |
| WHO performance status  |            |           |         |           |         |           |
| 0                       | 149        | 79        | 300     | 80        | 449     | 79        |
| 1–2                     | 40         | 21        | 77      | 20        | 117     | 21        |
| Age (years)             |            |           |         |           |         |           |
| <70                     | 134        | 71        | 267     | 71        | 401     | 71        |
| 70+                     | 55         | 29        | 110     | 29        | 165     | 29        |
| Median (quartiles)      | 66         | (62–71)   | 66      | (61–70)   | 66      | (62–70)   |
| Mean (SD)               | 66         | (7)       | 66      | (7)       | 66      | (7)       |
| Use of NSAID or aspirin |            |           |         |           |         |           |
| No use                  | 141        | 75        | 280     | 74        | 421     | 74        |
| Uses either             | 48         | 25        | 97      | 26        | 145     | 26        |
| PSA (ng/ml)             |            |           |         |           |         |           |
| Median (quartiles)      | 58         | (29–162)  | 55      | (20–194)  | 56      | (22–185)  |
| Mean (SD)               | 193        | (421)     | 274     | (631)     | 247     | (571)     |
| Ln PSA (ng/ml)          |            |           |         |           |         |           |
| Median (quartiles)      | 4.1        | (3.4–5.1) | 4.0     | (3.0–5.3) | 4.0     | (3.1–5.2) |
| Mean (SD)               | 4.2        | (1.4)     | 4.2     | (1.6)     | 4.2     | (1.5)     |
| RT planned              |            |           |         |           |         |           |
| M0, yes                 | 57         | 77        | 118     | 79        | 175     | 78        |
| M0, no                  | 17         | 23        | 32      | 21        | 49      | 22        |
| M1, yes                 | 12         | 10        | 21      | 9         | 33      | 10        |
| M1, no                  | 103        | 89        | 206     | 91        | 309     | 90        |
| Hypertension            |            |           |         |           |         |           |
| Yes (still fit for trial) | 64      | 34        | 149     | 40        | 213     | 38        |
| No                      | 125        | 66        | 227     | 60        | 352     | 62        |
| Year of randomisation   |            |           |         |           |         |           |
| 2011                    | 15         | 8         | 27      | 7         | 42      | 7         |
| 2012                    | 138        | 73        | 277     | 73        | 415     | 73        |
| 2013                    | 36         | 19        | 73      | 19        | 109     | 19        |
survival (sub-HR = 1.02, 95% CI 0.70–1.49). For non-prostate cancer-specific survival, with 23/149 deaths attributed to other causes, the sub-HR was 2.33 (95% CI 0.78–6.99). There was no evidence of heterogeneity of treatment effect by baseline metastases in either outcome.

**Other efficacy OMs**

Table 2 shows the effect size overall and by whether the patients had metastases at entry for FFS, PFS, MPFS and skeletal-related events. There is no evidence of heterogeneity of the treatment
effect by baseline metastases in any of these OMs. Figure 4 summarises the effect for all OMs.

**Safety**

The safety population includes people who started their allocated treatment. While nearly all patients allocated to AAP started it, a proportion of those patients allocated to receive docetaxel declined to start it. Table 3 summarises the worst toxicity reported for patients over their time on trial in the safety population and shows differing patterns for adverse events according to treatment. The prevalence of grade 3 or 4 toxicity in patients with assessments at 1 year without a prior FFS event was 11% SOC + DocP and 11% SOC + AAP; at 2 years this was 11% SOC + DocP and 11% SOC + AAP.

**Second-line treatment**

Figure 5 shows time from randomisation to any subsequent exposure to docetaxel or AR-targeted therapy with AAP or enzalutamide. Figure 6 shows time from an FFS event to reported exposure to selected treatments that are licensed for CRPC: docetaxel, AAP, enzalutamide. There was limited reported use of cabazitaxel, radium and sipuleucel-T at this point (not shown).
Discussion

We and others have previously shown a survival advantage for adding docetaxel (with or without prednisolone/prednisone) and for adding abiraterone acetate and prednisolone/prednisone, in patients starting long-term hormone therapy for the first time [4–11]. However, there is currently no direct evidence available to help clinicians or patients assess which combination might be better. Here, we reported a pre-specified (but not pre-powered) analysis using only patients who were randomised during a period of the study when recruitment to the two research arms overlapped. We used data collected prospectively from over 100 sites across two countries as part of a clinical trial protocol. The MAMS platform design of STAMPEDE, an approach sometimes referred to as a master protocol [16], facilitated this comparison. Separate, traditional, two-arm RCTs, would not have allowed any directly randomised comparative evidence to be available so soon.

Our recently reported overall treatment effect on survival, in STAMPEDE, for adding AAP compared with the SOC (HR = 0.63) [10] was larger than the previously-reported overall treatment effect, in STAMPEDE, on survival for adding DocP to the same SOC (HR = 0.78) [7]. The earlier secondary efficacy OMs favoured adding AAP over DocP, including FFS—perhaps unsurprising given the direct antiandrogenic action of AAP (around four in every five FFS events was driven only by a rise in PSA) and PFS (which excludes rising PSA). There was weak evidence favouring AAP for MPFS and no evidence of a difference in symptomatic skeletal events, prostate cancer-specific survival or OS.

Comparing the results indirectly of these two therapies by readers extracting data from STAMPEDE’s AAP and docetaxel papers [7, 10] may not be the most appropriate way to compare the relative effectiveness: the patient cohorts were all not randomised contemporaneously and there may be confounding biases when comparing the two datasets, in particular, many DocP patients had very limited salvage CRPC options compared with AAP patients, simply due to the timing of licences of new therapies (see below).

Importantly, the two therapies are being used in different ways. AAP is used until the patient has castrate-resistant prostate cancer (CRPC), often lasting many years and consequently exhausting a major therapy option for CRPC. In contrast, DocP is given as an 18-week course thus all CRPC options should remain available. Our data reveal important differences in the pattern of treatment failure yet we do not see any differences in survival, suggesting that the relative time spent before and after first-line treatment failure are quite different by initial treatment. This may explain why the early, often biochemically driven OMs, favour AAP but the later post CRPC end points such as skeletal events, prostate cancer-specific survival and OS show no good evidence of a difference. Men receiving DocP will thus spend longer with CRPC than men receiving AAP but with a broader range of more effective options available. Supplementary Figure S1, available at

Table 3. Worst adverse event (grade) reported over entire time on trial

| Safety population | SOC + Doc (n = 189) | SOC + AAP (n = 377) |
|-------------------|--------------------|--------------------|
| Number of patients included in analysis | 172 | 373 |
| Patients with an adverse event—no. (%) | 172 (100) | 370 (99) |
| Grade 1–5 adverse event | 86 (50) | 180 (48) |
| Grade 3–5 adverse events—no. (%) | 172 (100) | 370 (99) |
| Endocrine disorder | 15 (9) | 49 (13) |
| Febrile neutropenia | 29 (17) | 3 (1) |
| Neutropenia (neutrophils) | 22 (13) | 4 (1) |
| General disorder | 18 (10) | 21 (6) |
| Fatigue | 7 (4) | 8 (2) |
| Oedema | 1 (1) | 2 (1) |
| Musculoskeletal disorder | 9 (5) | 33 (9) |
| Cardiovascular disorder | 6 (3) | 32 (9) |
| Hypertension | 0 (0) | 12 (3) |
| Myocardial infarction | 1 (1) | 1 (1) |
| Cardiac dysrhythmia | 1 (1) | 5 (1) |
| Gastrointestinal disorder | 9 (5) | 28 (8) |
| Hepatic disorder | 1 (1) | 32 (9) |
| Increased AST | 0 (0) | 6 (2) |
| Increased ALT | 1 (1) | 23 (6) |
| Respiratory disorder | 12 (7) | 11 (3) |
| Dyspnoea | 4 (2) | 1 (1) |
| Renal disorder | 5 (3) | 20 (5) |
| Lab abnormalities | 9 (5) | 11 (3) |
| Hypokalaemia | 0 (0) | 3 (1) |

*The safety population includes patients who started their allocated treatment.
Figure 5. Time from randomisation to reported starting docetaxel, AAP, enzalutamide or AR-targeting therapy. Kaplan–Meier (survival) plots showing cumulative incidence of exposure to treatments after randomisation. Each step up the y-axis represents an event, namely starting that particular treatment. The number of patients contributing information (at risk) over time since randomisation is shown under the table. The number of patients with an event between these points is shown in brackets. For example, in Figure 4C between 24 and 36 months after randomisation, 4 patients on the SOC+DocP arm report starting abiraterone and (150/129)/4 are 17 are censored and may start in the future.

Figure 6. Time from failure-free survival event to subsequent treatment by allocated treatment. Kaplan–Meier (survival) plots showing cumulative incidence of exposure to treatments after a failure-free survival (FFS) event. Doc, docetaxel; AAP, abiraterone acetate + prednisolone; Enz, enzalutamide. Each step up the y-axis represents an event, namely starting that particular treatment.
A key limitation is that the comparison was opportunistic and not designed in the usual way, hence power is limited to detect any realistic differences. The trigger for the analysis was the reporting of our ‘abiraterone comparison’ data [10]. The unequal allocation ratio reflects the planned design of the comparisons. The allocated treatment being given was not masked for practical reasons. This, of course, allowed for relapse therapies to be given at the investigator’s discretion. We observed that after relapse, many patients received the treatment class that they had not received up-front.

Salvage options have changed over time: men recruited earlier to DocP [2005–2013] will have had very different options to those recruited later to AAP (2011–2014) when there were more CRPC therapies likely available, including AAP [17, 18], cabazitaxel [19], docetaxel [20, 21], enzalutamide [22, 23], radium-223 [24] and sipuleucel-T [25] (although not widely accessible in Europe). For this analysis, we limited ourselves to patients contemporaneously randomised to either arm to make this comparison as fair as possible. However, FFS events generally happen sooner with DocP than with AAP in time from randomisation and, therefore, calendar year (Table 4) may partially influence outcomes. Furthermore, a FFS event was more of an indication to change treatments on DocP; AAP continued beyond this point.

As far as we are aware there are no ongoing randomised trials directly comparing adding AAP versus adding docetaxel for patients starting long-term ADT. All of our published STAMPEDE data have contributed to the STOpCaP aggregate data network meta-analysis that has used all of the reported RCTs in metastatic patients to perform indirect comparisons and allow some assessment of potential ranking of effective therapies. This aggregate data analysis (co-submitted) will be supplemented by a forthcoming individual patient data (IPD) network meta-analysis which will hopefully provide a more accurate reflection of the temporal interval between the application of the two different therapies, to which STAMPEDE will contribute all relevant data. We will continue to follow-up patients for long-term OMs.

Considering their mechanisms of action and their proven oncological benefits, the question is raised of whether a combination of AAP plus docetaxel might lead to an approximately additive benefit of using them both, further extending survival. Randomised data on docetaxel with or without abiraterone will emerge from a subset the PEACE-1 trial (https://clinicaltrials.gov/ct2/show/NCT01957436), as will non-randomised, time-stratified data on abiraterone with or without docetaxel. Similarly comparative data will also emerge for enzalutamide, another AR-targeted therapy, from the ENZAMET trial (https://clinicaltrials.gov/ct2/show/NCT02446405) and with the combination of enzalutamide and AAP in STAMPEDE (Figure 1).

In conclusion, there are now two systemic therapies, DocP and AAP, which have shown a survival benefit from RCTs when added to treatment of patients starting long-term ADT for the first time. The evidence from our directly randomised data comparing these two therapies showed no evidence of a difference in overall or prostate cancer-specific survival, nor in other important outcomes such as symptomatic skeletal events, suggesting that both currently remain viable new standards-of-care.

**Acknowledgements**

**Independent oversight committee members**

**Independent Data Monitoring Committee:** John Yarnold (chair), Doug Altman, Ronald de Wit, Bertrand Tombal; Previous—Reg Hall, Chris Williams

**Trial Steering Committee:** Jonathan Ledermann (chair), Jan Erik Damber, Richard Emsley, Alan Horwich; Previous—John Fitzpatrick, David Kirk, Jim Paul

**Participating site list**

**Structure: City, Hospital** (Number of patients by data freeze: site PI; other investigators)
• Southamton General Hospital (75: Jones; Heath, Wheeler, Crabb)
• Southend University Hospital (114: Tsang; Ahmed, Chan)
• Southport and Formby District GH (46: Bhalla; Sivapalasuntharam, Sivapalasuntharam)
• St Leonards-on-Sea, Conquest Hospital (42: McKinna; Beesley, Lees)
• Stevenage, Lister Hospital (35: Hughes)
• Stockport, Stepping Hill Hospital (106: Logue; Coyle)
• Stockton-on-Tees, UH North Tees (28: Leaning; Shakespeare)
• Sunderland Royal Hospital (45: Azzabi)
• Sutton-in-Ashford, King’s Mill Hospital (64: Saunders)
• Sutton and London, Royal Marsden Hospital (162: Dearnley; Parker, Selvadurai)
• Swansea, Singleton (188: Wagstaff; Phan, Phan)
• Swindon, Great Western Hospital (52: Khan; Cole)
• Taunton, Musgrove Park Hospital (137: Gray; Graham, Varughese, Platinotios)
• Torbay District General Hospital (135: Lydon; Srinivasan)
• Tyne & Wear, S Tyneside District Hospital (6: Azzabi)
• Warrington Hospital (111: Syndikus; Tolan)
• Warwick Hospital (17: Chan; Stockdale)
• Wigan, Royal Albert Edward Infirmary (37: Tran)
• Wirral, The Clatterbridge Cancer Centre NHS Foundation Trust (128: Tolan; Syndikus, Ibrahim, Montazeri, Littler)
• Wolverhampton, New Cross Hospital (53: Gray; Sayers)
• Woolwich, Queen Elizabeth Hospital (18: Hughes)
• Worcestershire Royal Hospital (57: Capaldi; Bowen)
• Worthing Hospital (90: Nikapota)
• Wycombe Hospital (52: Sabharwal; Protheroe, Prwint)

Switzerland
• Basel Universitatsspital (5: Rentsch)
• Berne University Hospital (Inselspital) (5: Thalmann)
• Chur Kantonsspital Graubunden (31: Streb; Cathomas)
• Kantonsspital St Gallen (10: Engeler)
• Lausanne, Centre Hospital Univ Vaudois (7: Berthold; Jichlinski)

Trials Unit Staff (from 2011 onwards)

MRC Clinical Trials Unit at UCL
• Statisticians—Matthew Sydes, Max Parmar, Melissa Spears, Chris Brawley; Previously—Gordana Jovic, Rachel Jinks, Patrick Royston, Sophie Barthel, Babak Choodari-Oskooei, Daniel Batton, Andrew Embleton
• Project and Trial Managers—Claire Amos, Nafisah Atako; Claire Murphy, Joanna Calvert, Mazna Anjum, Chris Winans, Arlen Wilcox; Previously—Sharon Naylor, Neil Kelk, James Latham, Jacqui Nuttall, Karen Sanders, Tom Fairfield, Charlene Green, Francesca Schiavone, Katie Ward, Mazna Anjum, Anna Herasimtschuk, Jenny Petrie, Alanna Brown, Orla Prendiville
• Data Managers—Carly Au, Danielle Johnson, Lina Bergstrom, Tasmin Philips; Previously—Emma Donoghue, Tim Smith, Jacque Millett, Shama Hassan, Philip Pollock, Richard Gracie, Laura Van Dyck, Charlene Green, Elizabeth Clark, Sara Peres, Hannah Gardner, Dominic Hague, Katie Ward, Peter Vaughan, Eva Ades, Hannah Babiker, Zohrah Khan, Nargis Begum, Saba Khan, Jenna Grabey
• Data Scientists and Programmers—Nadine Van Looy, Zaheer Islam, Dominic Hague; Previously—Lindsey Masters, Will Cragg, Sajad Khan
• Clinicians—Clare Gilson, Alastair Ritchie; Previously—Sarah Meredith, Ruth Langley
• Trial Assistants—Stephanie Wetton, Amy Fiddament; Previously—Leigh Dobson, Alexandra Wadia, Nat Thorogood, Shanaz, Sohail, Tracey Fisher, Andrew Whitney

Swiss Group for Cancer Clinical Research
• Project and Trial Managers—Corinne Schar; Previously—Estelle Cassoly
• Patient and Public Involvement representatives—David Matheson, Robin Millman

Funding
The trial was sponsored by the UK Medical Research Council (MRC) and conducted by the MRC Clinical Trials Unit at UCL. In the UK the trial was supported by the UK Clinical Research Network, and funded by CRUK and the MRC, and in Switzerland, by the Swiss Group for Cancer Clinical Research (SAKK). Industry collaboration and support has been provided to STAMPEDE by Astellas, Clovis Oncology, Janssen, Novartis, Pfizer and Sanofi-Genzyme. MRC employees were central to the conduct of the trial and the development of this manuscript. Authors MRSy and MRSp accessed raw data. The funding bodies had no role in determining this publication.

Research support for trial: Cancer Research UK (CRUK_A12459), Medical Research Council (MRC_MC_UU_12023/25); Janssen, Sanofi-Aventis; Astellas, Clovis Oncology, Novartis, Pfizer.

DPD, JSdeB, GA and CCP acknowledge NHS funding to the NIHR Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and Institute of Cancer Research.

Disclosure
CA reports grants and non-financial support from Sanofi-Aventis, Novartis, Pfizer, Janssen, Astellas and Clovis Oncology during the conduct of the study. GA reports personal fees, grants and/or travel support from Janssen during the conduct of the study; personal fees and/or travel support from Astellas, Pfizer, Janssen, Millennium Pharmaceuticals, Ipsen, Ventana, Veridex, Novartis, Abbott Laboratories, ESSA Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Takeda and Sanofi-Aventis and grant support from AstraZeneca, Innocrin Pharma and Arno Therapeutics, outside the submitted work; in addition, GA’s former employer, The Institute of Cancer Research, receives royalty income from abiraterone and GA receives a share of this income through the ICR’s Rewards to Discoverers Scheme. AB reports personal fees and other from Sanofi, other from Bayer, other from Astra Zeneca, outside the submitted work. SB reports other...
from Janssen, outside the submitted work; and attendance at ESMO 2018 funded by Janssen. PC reports grants from Janssen, during the conduct of the study. AC reports funding from Prostate Cancer UK, Cancer Research UK, National Institute of Health Research, Medical Research Council and Astra Zeneca, outside the submitted work. SC reports grants and personal fees from Sanofi-Aventis and personal fees from Janssen Pharmaceutical, outside the submitted work. NWC reports personal fees from Janssen Pharmaceuticals, during the conduct of the study; personal fees from Janssen Pharmaceuticals, outside the submitted work; personal fees from Bayer and Astellas. WC reports personal fees from Janssen and Bayer, outside the submitted work. JDG reports other support as a local principal investigator for a study of radium-223 in prostate cancer funded by Bayer, and other support as a local principal investigator for a study of LHRH antagonist in prostate cancer funded by Millennium Pharmaceuticals, outside the submitted work. SG reports personal fees from Bayer, other from Bayer and CureVac, personal fees from Janssen Cilag, other from Janssen Cilag, personal fees from Dendreon Corporation, other from Astellas, personal fees from Millennium Pharmaceuticals, personal fees from Orion, Sanofi and MaxiVax SA, other from AAA Advanced Accelerator Applications International, Bristol-Myers Squibb, Ferring, Roche, Orion, Innocrin Pharmaceuticals, Sanofi, Novartis, Nektar Therapeutics and ProteoMedix, outside the submitted work. CG reports grants from Clovis Oncology, outside the submitted work. NDJ reports grants and personal fees from Sanofi and Novartis, during the conduct of the study; grants and personal fees from Janssen, Astellas and Bayer, outside the submitted work. RJJ reports grants from Sanofi, and grants and non-financial support from Novartis, during the conduct of the study; grants, personal fees and non-financial support from Sanofi and Novartis, grants and personal fees from Janssen, Astellas and Bayer, outside the submitted work. JL reports personal fees, non-financial support and other from Janssen, Astellas and Sanofi, outside the submitted work. ZIM reports the conduct of the study; other from AstraZeneca, Pfizer, GlaxoSmithKline, Taiho, Daiichi, Novartis, Genmab, Merck Serano, Merck and Genentech/Roche, outside the submitted work. DPD reports other from UK National Institute for Health Research Clinical Research Network (NIHR CRN), during the conduct of the study; grants from Cancer Research UK; personal fees and other from Takeda, Amgen, Astellas and Sandoz, personal fees, non-financial support and other from Janssen, personal fees and other from Cadence Research, other from Clovis, personal fees and non-financial support from ISSECAM, outside the submitted work; in addition, DPD has a patent GB9305269.17-substituted steroids useful in cancer treatment with royalties paid to Janssen Pharmaceutical Company. DF reports honoraria from Janssen, Novartis and Sanofi, outside the submitted work. MKBP reports grants and non-financial support from Sanofi-Aventis, Novartis, Pfizer, Janssen and Astellas, during the conduct of the study; other from ICR and Janssen, research funding and speaker’s honoraria from Bayer, outside the submitted work. CCP reports personal fees from Janssen, research funding and speaker’s honoraria from Bayer, MKBP reports grants and non-financial support from Janssen, during the conduct of the study; grants and non-financial support from Astellas, Clovis Oncology, Novartis, Pfizer and Sanofi, outside the submitted work. AP reports personal fees from Ipsen, Bayer, Roche and BMS, grants from Merck, personal fees from Merck, outside the submitted work. JMR reports personal fees from Janssen (lecture fee), outside the submitted work. DM reports conference travel costs from Ipsen and Astellas, outside the submitted work. MRSp reports grants and non-financial support from Sanofi-Aventis, Novartis, Pfizer, Janssen and Astellas, during the conduct of the study; and personal fees from Eli-Lilly, outside the submitted work. ST reports other from Sanofi, other support from Astellas, personal fees from Astellas and other support from Janssen, outside the submitted work. ST reports travel grants from Janssen. JW reports a paid consultancy for Janssen. All remaining authors have declared no conflicts of interest.

References

1. Widmark A, Klepp O, Solberg A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SPUO-3): an open randomised phase III trial. Lancet 2009; 373(9660): 301–308.
2. Mason MD, Parulekar WR, Sydes MR et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. JCO 2015; 33(19): 2143–2150.
3. Mottet N, Peneau M, Mazeron JJ et al. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 2012; 62(2): 213–219.
4. Fizazi K, Lesaunier F, Delva R et al. A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Cancer 2012; 48(2): 209–217.
5. Fizazi K, Faivre L, Lesaunier F et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 2015; 16(7): 787–794.
6. Gravis G, Boher JM, Joly F et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial. Eur Urol 2016; 70(2): 256–262.
7. James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387(10024): 1163–1177.
8. Vale CL, Burdett S, Rydzewska LH et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 2016; 17(2): 243–256.
9. Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373(8): 737–746.
10. James ND, de Bono JS, Spears MR et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017; 377(4): 338–351.
11. Fizazi K, Tran N, Fein I et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017; 377(4): 352–360.
12. Sydes MR, Parmar MK, Mason MD et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials 2012; 13(1): 168.
13. Parmar MK, Sydes MR, Cafferty FH et al. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: multi-arm, multi-stage platform, umbrella and basket protocols. Clinical Trials 2017; 14(5): 451–461.
14. Sydes MR, Parmar MK, James ND et al. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials 2009; 10(1): 39.
15. Xie W, Regan MM, Buyse M et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. JCO 2017; 35(27): 3097–3104.
16. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 2017; 377(1): 62–70.
17. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368(2): 138–148.
18. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364(21): 1995–2005.
19. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376(9747): 1147–1154.
20. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513–1520.
21. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502–1512.
22. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367(13): 1187–1197.
23. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371(5): 424–433.
24. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369(3): 213–223.
25. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363(5): 411–422.